SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Nazara Technologies, Hazoor Multi Projects and HDFC to see some action today

Housing Development Finance Corporation Ltd. - (Amalgamated) | Finance - Housing | BFSI | BSE: 500010 | NSE: HDFC

23 Apr 2021 Evaluate

Nazara Technologies has entered into a Share Purchase Agreement (SPA) on April 22, 2021 with Sankalp Sharma and Absolute Sports (ASPL) for acquisition of further stake of 1.40% equity stake (on fully diluted basis) for a consideration of Rs 96.16 lakh in ASPL, a subsidiary of the Company. Post completion of the said transaction, the stake of the Company in ASPL shall increase from 63.90% to 65.30%.

Hazoor Multi Projects has received work order of Rs 6,84,00,000 for completion of Balance work of 'National Highway No 548-A from Section Waken Pali to 2 lane with paved shoulder' from Varaha Infra.

Housing Development Finance Corporation (HDFC) has concluded the sale of 47,75,241 equity shares of Re 1 each, representing 24.48% of the equity capital of Good Host Spaces (Good Host) to Baskin Lake Investments, at a price of Rs 452.71 per equity share, aggregating to a consideration of Rs 216.18 crore. Post sale, Good Host has ceased to be an associate of the Corporation.

TCPL Packaging has subscribed additional 10,00,000 fully paid up equity shares of face value of Rs 10 each of TCPL Innofilms, the wholly owned subsidiary of the Company.

Wipro is going to achieving Net-Zero Greenhouse Gas (GHG) emissions by 2040 in line with the objective of the Paris Agreement to cap temperature rise to 1.5 degree Celsius. The company also set an intermediate target of a 55 per cent reduction in GHG emissions by 2030 in absolute emission levels compared to its base year of 2016-17 (April-March).

Gland Pharma has received approval from the United States Food and Drug Administration (US FDA) for generic Foscarnet Sodium Injection, 6000 mg/250 mL (24 mg/mL) Single-Dose Bag for Infusion. Generic Foscarnet Sodium Injection is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Foscavir Injection, 24 mg/mL, of Clinigen Healthcare. With this approval, Gland Pharma secured the first generic offering status in Single-Dose Bag for Infusion.

Cyient has reported results for fourth quarter and year ended March 31, 2021. The company has reported net profit of Rs 46.10 crore for the quarter under review against net loss of Rs 1 crore for the same quarter in the previous year. However, total income of the company decreased by 7.14% at Rs 347 crore for Q4FY21 as compared Rs 373.70 crore for the corresponding quarter previous year. On the consolidated basis, the company has reported over 2-fold jump in its net profit at Rs 103.10 crore for the quarter under review as compared to Rs 45.20 crore for the same quarter in the previous year. Total income of the company marginally increased by 0.52% at Rs 1,133.40 crore for Q4FY21 as compared Rs 1,127.50 crore for the corresponding quarter previous year.

HDFC-Amalgamated Share Price

2729.95 0.00 (0.00%)

12-Jul-2023 18:01 View Price Chart

Peers

Company Name	CMP
LIC Housing Finance	541.00
Housing & Urban Dev.	200.40
Bajaj Housing Financ	90.46
Piramal Finance	1652.70
PNB Housing Finance	926.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Nazara Technologies, Hazoor Multi Projects and HDFC to see some action today

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.